Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound having the following general formula (I):



(I)

wherein A is -(CHR_3)- or -(C=O)-, B is -(CHR_4)-, -(C=O)-, D is –(CHR_5)- or –(C=O)-, E is –(ZR_6)-, -(C=O)-, G is –(XR_7)$_n$-, ~~-(CHR_7)-(NR_8)-, -(C=O)-(XR_9)-, or -(C=O)-,~~ W is -Y(C=O)-, -(C=O)NH-, -(SO_2)- or nothing, Y is oxygen, sulfur or -NH-, X and Z ~~is~~ are independently nitrogen or CH, ~~n=0 or 1;~~ and R_1, R_2, R_3, R_4, R_5, R_6, and R_7~~, R_8 and R_9~~ are the same or different and independently selected from an amino acid side chain moiety, ~~or~~ an amino acid side chain derivative~~ thereof, the remainder of the molecule~~, a linker, and a solid support, ~~and stereoisomers thereof~~with the proviso that when Z is CH, then X is nitrogen.

2. (Currently Amended) The compound of claim 1, wherein R_1, R_2, R_3, R_4, R_5, R_6, and R_7~~, R_8 and R_9~~ are independently selected from the group consisting of aminoC_{2-5}alkyl, guanidinoC_{2-5}alkyl, C_{1-4}alkylguanidinoC_{2-5}alkyl, diC_{1-4}alkylguanidino-C_{2-5}alkyl, amidinoC_{2-5}alkyl, C_{1-4}alkylamidinoC_{2-5}alkyl, diC_{1-4}alkylamidinoC_{2-5}alkyl, C_{1-3}alkoxy, Phenyl, substituted phenyl (where the substituents on the phenyl are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), benzyl, substituted benzyl (where the substituents on the benzyl are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), naphthyl, substituted

naphthyl (where the substituents on the naphthyl are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), bis-phenyl methyl, substituted bis-phenyl methyl (where the substituents on the bis-phenyl methyl are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), pyridyl, substituted pyridyl, (where the substituents on the pyridyl are independently selected from one or more of amino amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), pyridylC_{1-4}alkyl, substituted pyridylC_{1-4}alkyl (where the pyridine substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), pyrimidylC_{1-4}alkyl, substituted pyrimidylC_{1-4}alkyl (where the pyrimidine substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, ~~or~~ nitro, carboxy, cyano, sulfuryl or hydroxyl), triazin-2-yl-C_{1-4}alkyl, substituted triazin-2-yl-C_{1-4}alkyl (where the triazine substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), imidazoC_{1-4}alkyl, substituted imidazol C_{1-4}alkl (where the imidazole sustituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl or hydroxyl), imidazolinylC_{1-4}alkyl, N-amidinopiperazinyl-N-C_{0-4}alkyl, hydroxyC_{2-5}alkyl, C_{1-5}alkylaminoC_{2-5}alkyl, hydroxyC_{2-5}alkyl, C_{1-5}alkylaminoC_{2-5}alkyl, C_{1-5}dialkylaminoC_{2-5}alkyl, N-amidinopiperidinylC_{1-4}alkyl and 4-aminocyclohexylC_{0-2}alkyl.

3. (Canceled)

4. (Canceled)

5. (Currently Amended) The compound of claim 1, wherein A is –(C=O)-, B is –(CHR_4)-, D is –(C=O)-, E is –(ZR_6)-, G is $(XR_7)_n$-, and the compound has the following general formula (IV):



(IV)

wherein R_1, R_2, R_4, R_6, R_7, W, X and ~~n~~ Z are as defined in claim 1~~, and Z is nitrogen or CH, with the proviso that when Z is nitrogen, then n is zero, and when Z is CH, then X is nitrogen and n is not zero~~.

6. (Original) The compound of claim 5, wherein the compound has the following general formula (VI):



wherein R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino,

hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; or a bicyclic aryl group having 8 to 11 ring members, which may have 1 to 3 heteroatoms selected from nitrogen, oxygen or sulfur; R_b is a monocyclic aryl group having 5 to 7 ring members, which may have 1 to 2 heteroatoms selected from nitrogen, oxygen or sulfur, and aryl ring in the compound may have one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups; Rc is a saturated or unsaturated C_{1-6}alkyl, C_{1-6}alkoxy, perfluoro C_{1-6}alkyl group; and X_1, X_2, and X_3 may be the same or different and independently selected from hydrogen, hydroxyl, and halide.

7. (Previously Presented) The compound of claim 6, wherein R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; a naphthyl group; a quinolinyl group; or an isoquinolinyl group; and R_b is phenyl, pyridyl or piperidyl, all of which may be substituted with one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy groups.

8. (Previously Presented) The compound of claim 6, wherein R_a is a phenyl group; a substituted phenyl group having one or more substituents wherein the one or more substituents are independently selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl groups; a benzyl group; a substituted benzyl group with one or more substituents where the one or more substituents are independently

selected from one or more of amino, amidino, guanidino, hydrazino, amidazonyl, C_{1-4}alkylamino, C_{1-4}dialkylamino, halogen, perfluoro C_{1-4}alkyl, C_{1-3}alkoxy, nitro, carboxy, cyano, sulfuryl, and hydroxyl group; or a naphthyl group; and R_b is phenyl, which may be substituted with one or more substituents selected from a group consisting of halide, hydroxy, cyano, lower alkyl, and lower alkoxy group.

9. (Currently Amended) The compound of claim 1, wherein R_1, R_2, R_3, R_4, R_5, R_6, or R_7, ~~R_8 or R_9~~ is joined to a solid support or solid support derivatives.

10. (Currently Amended) The compound of claim 2, wherein R_1, R_2, R_3, R_4, R_5, R_6, or R_7, ~~R_8 or R_9~~ is joined to a solid support or solid support derivatives.

11. (Currently Amended) The compound of claim 3, wherein R_1, R_2, R_3, R_4, R_5, R_6, or R_7, ~~R_8 or R_9~~ is joined to a solid support or solid support derivatives.

12. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable carrier.

13. (Previously Presented) The pharmaceutical composition of claim 12 comprising a safe and effective amount of the compound.

14. (Previously Presented) A library of compounds, comprising at least one compound according to claim 1.

15. (Original) A method of identifying a biologically active compound, comprising contacting the library of claim 14 with a target to detect or screen the biologically active compound.

16. (Previously Presented) A method for carrying out a binding assay, comprising:

a) providing a composition comprising a first co-activator and an interacting protein, said first co-activator comprising a binding motif of LXXLL, LXXLI or FXXFF wherein X is any amino acid;

b) combining the first co-activator and the interacting protein with a test compound; and

c) detecting alteration in binding between the first co-activator and the interacting protein in the presence of the compound;

wherein the test compound is selected from a compound of claim 1.

17. (Original) The method of claim 16, wherein said interacting protein is a transcription factor or a second co-activator.

18. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of RIP140; SRC-1 (NCoA-1); TIF2 (GRIP-1; SRC-2); p (CIP; RAC3; ACTR; AIB-1; TRAM-1; SRC-3); CBP (p300); TRAPs (DRIPs); PGC-1; CARM-1; PRIP (ASC-2; AIB3; RAP250; NRC); GT-198; and SHARP (CoAA; p68; p72).

19. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of TAL 1; p73; MDm2; TBP; HIF-1; Ets-1; RXR; p65; AP-1; Pit-1; HNF-4; Stat2; HPV E2; BRCA1; p45 (NF-E2); c-Jun; c-myb; Tax; Sap 1; YY1; SREBP; ATF-1; ATF-4; Cubitus; Interruptus; Gli3; MRF; AFT-2; JMY; dMad; PyLT: HPV E6; CITTA; Tat; SF-1; E2F; junB; RNA helicase A; C/EBP β; GATA-1; Neuro D; Microphthalimia; E1A; TFIIB; p53; P/CAF; Twist; Myo D; pp9O RSK; c-Fos; and SV40 Large T.

20. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of ERAP140; RIP140; RIP160; Trip1; SWI1 (SNF); ARA70; RAP46; TIF1; TIF2; GRIP1; and TRAP.

21. (Original) The method of claim 16, wherein said interacting protein is selected from the group consisting of VP16; VP64; p300; CBP; PCAF; SRC1 PvALF; AtHD2A; ERF-2; OsGAI; HALF-1; C1; AP-1; ARF-5; ARF-6; ARF-7; ARF-8; CPRF1; CPRF4; MYC-RP/GP; and TRAB1.

22. (Original) The method of claim 16, wherein said first co-activator is CBP or p300.

23. (Previously Presented) A method for inhibiting tumor growth comprising administering to a mammalian subject having a tumor a compound according to claim 1 in an amount effective to inhibit the growth of the tumor in the mammalian subject.

24. (Original) The method of claim 23 wherein the tumor is cancerous.

25. (Canceled)

26. (Previously Presented) A method of treating or preventing cancer comprising administering to a subject in need thereof a compound according to claim 1 in an amount effective to treat or prevent the cancer.

27. (Original) The method of claim 26 wherein the cancer is colorectal cancer.

28. (Original) The method of claim 26 wherein the compound or the composition is administered in combination with an anti-neoplastic agent.

29. (Original) The method of claim 28 wherein the anti-neoplastic agent is selected from the group consisting of 5-FU, taxol, cisplatin, mitomycin C, tegafur, raltitrexed, capecitabine, and irinotecan.

30. (Previously Presented) A method of treating or preventing restenosis associated with angioplasty comprising administering to a subject in need thereof an amount of a compound according to claim 1, where the amount is effective to prevent the restenosis.

31. (Previously Presented) A method of treating or preventing polycystic kidney disease comprising administering to a subject in need thereof an amount of a compound according to claim 1, where the amount is effective to treat the polycystic kidney disease.

32. (Previously Presented) A method of treating or preventing aberrant angiogenesis disease comprising administering to a subject in need thereof an amount of a compound according to claim 1, where the amount is effective to treat the aberrant angiogenesis disease.

33. (Previously Presented) A method of treating or preventing rheumatoid arthritis disease comprising administering to a subject in need thereof an amount of a compound according to claim 1, where the amount is effective to treat the rheumatoid arthritis disease.

34. (Previously Presented) A method of treating or preventing ulcerative colitis comprising administering to a subject in need thereof an amount of a compound according to claim 1, where the amount is effective to treat the ulcerative colitis.

35. (Previously Presented) A method for treating or preventing tuberous sclerosis complex (TSC) comprising administering to a subject in need thereof an amount of a compound of claim 1, where the amount is effective to treat or prevent TSC.

36. (Previously Presented) A method for treating or preventing a KSHV-associated tumor comprising administering to a subject in need thereof an amount of a compound of claim 1, where the amount is effective to treat or prevent the KSHV-associated tumor.

37-42. (Canceled)